A non-interventional study to assess the long-term safety and efficacy of osilodrostat in patients with endogenous Cushing’s syndrome (LINC 6)

Study identification

• EU PAS number:
  EUPAS46496
• Study ID:
  46497
• Official title and acronym:
  A non-interventional study to assess the long-term safety and efficacy of osilodrostat in patients with endogenous Cushing’s syndrome (LINC 6)
• DARWIN EU® study:
  No
• Study countries:
  France

  Germany

  Italy

  Netherlands

  United States
• Study status:
  Ongoing

Study timelines

Date when funding contract was signed

Actual:22/12/2021

Study start date

Actual:13/06/2022

Date of final study report

Planned:31/12/2027

Sources of funding

More details on funding

Recordati AG

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable